Similarly, the Chinese Guidelines for the Prevention and Control of Type 2 Diabetes Mellitus (2020) advocate for GLP-1 RAs or SGLT-2is in T2DM patients with ASCVD or cardiovascular risk factors, regardless of glycosylated hemoglobin (HbA1c) levels, provided no contraindications exist (Soci and ety, 2021). The gene discussed is GLP1R; the disease is atherosclerosis.